This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Donald W. Black, MD; Robert Wesner, MD; Wayne Bowers, PhD; Jenelle Gabel, RN

Arch Gen Psychiatry. 1993;50(1):44-50.

Abstract
• Seventy-five outpatients with moderate to severe panic disorder were randomly assigned to receive 8 weeks of fluvoxamine, cognitive therapy, or placebo. Fifty-five patients completed the treatment protocol. Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables. Subjects receiving cognitive therapy also showed improvement, but this improvement did not significantly differ from the experience of the placebo-treated group for most comparisons. Fluvoxamine was superior to cognitive therapy for many ratings, but cognitive therapy was not superior to fluvoxamine on any rating. Fluvoxamine also produced improvement earlier than cognitive therapy. At the main comparison point (week 4), 57% (13/23) of patients receiving fluvoxamine were rated moderately improved or better vs 40% (8/20) of the group given cognitive therapy and 22% (5/23) of the placebo-treated group. At that point, 43% (10/23) of the fluvoxamine recipients vs 25% (5/20) of cognitive therapy and 4% (1/23) of placebo recipients were free of panic attacks

Author Affiliations
From the Department of Psychiatry, University of Iowa College of Medicine, Iowa City.

Footnotes
Accepted for publication December 9, 1991.

Reprint requests to Department of Psychiatry, Medical Education Building, 500 Newton Rd, Iowa City, IA 52242 (Dr Black).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Patient Management Exercise FOR PSYCHOPHARMACOLOGY
Levine and Albucher
Focus 2006;4:496.
ABSTRACT | FULL TEXT  

Cost-utility of brief psychological treatment for depression and anxiety
ROIJEN et al.
Br. J. Psychiatry 2006;188:323-329.
ABSTRACT | FULL TEXT  

An Effect-Size Analysis of the Relative Efficacy and Tolerability of Serotonin Selective Reuptake Inhibitors for Panic Disorder
Otto et al.
Am. J. Psychiatry 2001;158:1989-1992.
ABSTRACT | FULL TEXT  

Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial
MICHELSON et al.
Br. J. Psychiatry 2001;179:514-518.
ABSTRACT | FULL TEXT  

Comparing Psychotherapy and Pharmacotherapy
GOULD
Am. J. Psychiatry 2001;158:1164-1164.
FULL TEXT  

Flawed Meta-Analyses Comparing Psychotherapy With Pharmacotherapy
Klein
Am. J. Psychiatry 2000;157:1204-1211.
ABSTRACT | FULL TEXT  

Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder: A Randomized Controlled Trial
Barlow et al.
JAMA 2000;283:2529-2536.
ABSTRACT | FULL TEXT  

Fluvoxamine Pharmacotherapy of Anxiety Disorders in Later Life: Preliminary Open-Trial Data
Wylie et al.
J Geriatr Psychiatry Neurol 2000;13:43-48.
ABSTRACT  

Sertraline in the Treatment of Panic Disorder: A Flexible-Dose Multicenter Trial
Pollack et al.
Arch Gen Psychiatry 1998;55:1010-1016.
ABSTRACT | FULL TEXT  

Sertraline in the Treatment of Panic Disorder: A Double-Blind Multicenter Trial
Pohl et al.
Am. J. Psychiatry 1998;155:1189-1195.
ABSTRACT | FULL TEXT  

Comparison of Aerobic Exercise, Clomipramine, and Placebo in the Treatment of Panic Disorder
Broocks et al.
Am. J. Psychiatry 1998;155:603-609.
ABSTRACT | FULL TEXT  

Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
Ballenger et al.
Am. J. Psychiatry 1998;155:36-42.
ABSTRACT | FULL TEXT  

Stopping panic attacks
DTB 1997;35:58-62.
ABSTRACT | FULL TEXT  

Advances in the Psychosocial Treatment of Anxiety Disorders: Implications for National Health Care
Barlow and Lehman
Arch Gen Psychiatry 1996;53:727-735.
ABSTRACT  

A cognitive dysfunction in anxiety and its amelioration by effective treatment with SSRIs
Weinstein and Nutt
J Psychopharmacol 1995;9:83-89.
ABSTRACT  

The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man
Bailey et al.
J Psychopharmacol 1995;9:137-141.
ABSTRACT